Agios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting

November 1, 2017

– First Data From Ivosidenib Phase 1 Expansion in R/R AML and Phase 1 Frontline AML Combination Studies to be Highlighted in Oral Presentations –

– Company to Host Investor Event and Webcast on December 11, 2017–

CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that new data from the company's lead programs will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, December 9-12, 2017.

In total, four abstracts led by Agios describing new clinical data from the company's cancer and rare genetic diseases programs have been accepted for presentation at ASH. Two additional abstracts from Celgene and Boston Children's Hospital have also been accepted.

The accepted abstracts are listed below and are now available online on the ASH conference website: https://ash.confex.com/ash/2017/webprogram/start.html.

Oral Presentations

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Date & Time: Monday, December 11, 2017 at 11:00 a.m. ET
Session Title: 613. AML: Clinical Studies: Novel Therapies for AML and APL
Abstract Number: 639
Location: Building B, Level 5, Murphy BR 1-2

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
Date & Time: Monday, December 11, 2017 at 3:45 p.m. ET
Session Title: 616. AML: Novel Therapy, Excluding Transplantation: Emerging Molecularly Targeted Therapies in AML
Abstract Number: 725
Location: Building B, Level 5, Murphy BR 1-2

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Date & Time: Monday, December 11, 2017 at 4:00 p.m. ET
Session Title: 616. AML: Novel Therapy, Excluding Transplantation: Emerging Molecularly Targeted Therapies in AML
Abstract Number: 726
Location: Building B, Level 5, Murphy BR 1-2

Poster Presentations

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML
Date & Time: Sunday, December 10, 2017 at 6:00 p.m. ET
Session Title: 617. AML: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Abstract Number: 2684
Location: Building A, Level 1, Hall A2

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency
Date & Time: Sunday, December 10, 2017 at 6:00 p.m. ET
Session Title: 101. Red Cells & Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Abstract Number: 2194
Location: Building A, Level 1, Hall A2

Genotype-Phenotype Correlation and Molecular Heterogeneity in Pyruvate Kinase Deficiency: Data from the PKD Natural History Study
Date & Time: Monday, December 11, 2017 at 6:00 p.m. ET
Session Title: 101. Red Cells & Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster III
Abstract Number: 3479
Location: Building A, Level 1, Hall A2

Investor Event and Webcast Information
Agios will host an investor event on Monday, December 11, 2017 beginning at 8:00 p.m. ET in Atlanta to review data presented at ASH. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com.

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved

oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of Agios' product candidates, including enasidenib, ivosidenib, and AG-348; its plans, strategies and expectations for its and its collaborator's development of enasidenib, ivosidenib, and AG-348; its plans regarding future data presentations; and the potential benefit of its strategic plans and focus. The words "anticipate," "expect," "intend," "potential," "milestone," "goal," "will," "on track," "upcoming," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios or its collaborator, Celgene, is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreements with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor & Public Relations
Renee.Leck@agios.com

Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
Holly.Manning@agios.com

Source: Agios Pharmaceuticals, Inc.